We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Long‐Term Treatment and Effect of Discontinuation of Calcifediol in Postmenopausal Women with Vitamin D Deficiency: A Randomized Trial.
- Authors
Pérez‐Castrillón, José Luis; Dueñas‐Laita, Antonio; Gómez‐Alonso, Carlos; Jódar, Esteban; del Pino‐Montes, Javier; Brandi, Maria Luisa; Cereto Castro, Fernando; Quesada‐Gómez, José Manuel; Gallego López, Laura; Olmos Martínez, José Manuel; Alhambra Expósito, María Rosa; Galarraga, Bernat; González‐Macías, Jesús; Neyro, José Luis; Bouillon, Roger; Hernández‐Herrero, Gonzalo; Fernández‐Hernando, Nieves; Chinchilla, Sandra P.
- Abstract
Vitamin D plays a major role in bone health and probably also in multiple extraskeletal acute and chronic diseases. Although supplementation with calcifediol, a vitamin D metabolite, has demonstrated efficacy and safety in short‐term clinical trials, its effects after long‐term monthly administration have been studied less extensively. This report describes the results of a 1‐year, phase III‐IV, double‐blind, randomized, controlled, parallel, multicenter superiority clinical trial to assess the efficacy and safety of monthly calcifediol 0.266 mg versus cholecalciferol 25,000 IU (0.625 mg) in postmenopausal women with vitamin D deficiency (25(OH)D < 20 ng/mL). A total of 303 women were randomized and 298 evaluated. Patients were randomized 1:1:1 to calcifediol 0.266 mg/month for 12 months (Group A1), calcifediol 0.266 mg/month for 4 months followed by placebo for 8 months (Group A2), and cholecalciferol 25,000 IU/month (0.625 mg/month) for 12 months (Group B). By month 4, stable 25(OH)D levels were documented with both calcifediol and cholecalciferol (intention‐to‐treat population): 26.8 ± 8.5 ng/mL (Group A1) and 23.1 ± 5.4 ng/mL (Group B). By month 12, 25(OH)D levels were 23.9 ± 8.0 ng/mL (Group A1) and 22.4 ± 5.5 ng/mL (Group B). When calcifediol treatment was withdrawn in Group A2, 25(OH)D levels decreased to baseline levels (28.5 ± 8.7 ng/mL at month 4 versus 14.4 ± 6.0 ng/mL at month 12). No relevant treatment‐related safety issues were reported in any of the groups. The results confirm that long‐term treatment with monthly calcifediol in vitamin D‐deficient patients is effective and safe. The withdrawal of treatment leads to a pronounced decrease of 25(OH)D levels. Calcifediol presented a faster onset of action compared to monthly cholecalciferol. Long‐term treatment produces stable and sustained 25(OH)D concentrations with no associated safety concerns. © 2023 Faes Farma SA. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
- Subjects
VITAMIN D deficiency; CALCIFEDIOL; TERMINATION of treatment; POSTMENOPAUSE; BONE health
- Publication
Journal of Bone & Mineral Research, 2023, Vol 38, Issue 4, p471
- ISSN
0884-0431
- Publication type
Article
- DOI
10.1002/jbmr.4776